In addition, downregulation of GAS5 has been associated with chemoresistance in some malignant neoplasms, by affecting the sensitivity to adriamycin in gastric cancer [33], trastuzumab in breast cancer [34], mTOR inhibition in prostate cancer [35], and EGFR tyrosine kinase inhibition in wide-type EGFR NSCLC [20]. Here, GAS5 is linked to prostate cancer.